R&D Models: Lessons from Vaccine History
Columbia University - Department of Population and Family Health; Policy Analysis, International AIDS Vaccine Initiative
affiliation not provided to SSRN
Technological Change Lab, Columbia University
June 1, 2007
A preventive HIV vaccine offers the best hope for ending the AIDS pandemic. Scientific evidence suggests that an HIV vaccine is possible, and funding for HIV vaccine research and development (R&D) has increased substantially in recent years. The speed of progress toward an HIV vaccine will depend on the management of the effort as well as on its scale, however, and organizational issues have been the subject of vigorous debate. With this paper, we seek to shed light on these debates by examining the history of vaccine development, as well as some examples of large R&D initiatives in other areas. We focus on two issues: the roles of the public and private sectors, and the merits and risks of strong central direction of R&D. We also consider the scientific, regulatory, and institutional changes that complicate extrapolation from past experience to the case of HIV vaccines. Our analysis draws on extensive interviews with experts in the field as well as a literature review.
Number of Pages in PDF File: 60
Keywords: HIV vaccine, research and development, public and private sector
JEL Classification: O19, O31, O32, H41, H42, H57working papers series
Date posted: March 5, 2008 ; Last revised: October 13, 2008
© 2013 Social Science Electronic Publishing, Inc. All Rights Reserved.
This page was processed by apollo4 in 0.375 seconds